Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Mana.bio
(https://mana.bio) 📸 Data Snapshot: May 31, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Programmable Drug Delivery | Mana.bio (https://mana.bio)
Programmable Drug Delivery | Mana.bio
Mana.bio is an AI-based drug delivery startup specializing in programmable drug delivery and gene therapy, with a focus on lipid nanoparticles (LNPs), RNA-based therapeutics, DNA therapeutics, and vaccines.
NAV_HEADER_HEADING_REPEATED_BODY Technology | Mana.bio (https://mana.bio/technology/)
Technology | Mana.bio
At Mana.bio, we are pioneering a new era in genetic medicine through our unique integration of machine learning and lipid nanoparticle (LNP) design.
NAV_HEADER_HEADING_REPEATED_BODY Team (https://mana.bio/team/)
Team
NAV_HEADER LNP patents map | Mana.bio (https://mana.bio/fto/)
LNP patents map | Mana.bio
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://mana.bio) Programmable Drug Delivery | Mana.bio
[IMG: Small-Polygons-Header.png] [IMG: Manabio logo] Mana.bio is an AI based drug delivery startup, focusing on gene therapy including DNA and RNA-based therapeutics, and vaccines. We are on a mission to disrupt the drug delivery space using combined forces of machine learning and nanotechnology.Vision [H2] Drug Delivery [IMG: Drug Delivery] [IMG: Drug Delivery] [IMG: Machine Learning] [IMG: Machine Learning] [IMG: Machine Learning] [H2] Machine Learning [IMG: Nanotechnology] [IMG: Nanotechnology] [IMG: Nanotechnology] [H2] Nanotechnology Technology [IMG: polygon-techs-3.png] [H4] The technology The technology is powered by an integration of machine learning and nanotechnology in order to identify formulations of lipid nanoparticles drug delivery systems.Read More [IMG: Machine learning and nanotechnology illustration] [H4] ChatLNP - LNP AI Agent Mana introduces Mina, the first AI Agent built specifically for lipid nanoparticles. Quickly explore curated literature, predict LNP properties, and optimize formulations. Mina empowers scientists, formulation experts, and biotech teams to move faster and better. Try Mina now [IMG: BG-Gree.png] [IMG: 124915.jpg] [H4] The team Mana is founded and led by a team of repeat entrepreneurs and highly regarded experts in the field of drug delivery, machine learning and software development which are inspired by the potential of combining advanced technologies in biology and medicine.Meet the Team
SUB-PAGE (https://mana.bio/technology/) Technology | Mana.bio
[IMG: Small-Polygons-Header.png] At Mana.bio, we are pioneering a new era in genetic medicine through our unique integration of machine learning and lipid nanoparticle (LNP) design. [IMG: genetic medicine] Our AI-driven approach transcends traditional limitations, enabling precise and optimized formulations for extrahepatic delivery of nucleic acid therapeutics and vaccines. By harnessing the power of AI to significantly cut down the time for development and to achieve novel IP-protected results, we are not only advancing the field of gene therapy but also unlocking unprecedented possibilities for collaborations and innovations in the biotech and pharmaceutical industries. [IMG: Circle] [H4] Mana.bio Platform desin [IMG: Design] [H4] Design Mana.bio's AI platform designs novel lipid nanoparticle candidates in silico using its machine learning models that predict desirable properties to select best-in-class cell specific tissue-targeted LNPs. [IMG: Rectanglles.png] Built [H4] Build Mana.bio uses its high-throughput capabilities to synthesize and make dozens of lipid nanoparticle formulations per week, transforming computational models into physical entities using automated manufacturing pipelines. [IMG: lipid nanoparticle formulations] Test [IMG: lipid nanoparticle formulations] [H4] Test Mana.bio thoroughly evaluates each constructed lipid nanoparticle through automated, high-throughput screening infrastructure including assays that analyze efficacy, safety and physicochemical properties to identify top candidates, while continuously generating data to further improve the machine learning models predictions. [IMG: Rectanglles.png] Learn [H4] Learn [H2] All experimental results are digitally stored and instantly transferred into the AI platform training set. This is how the machine learning models are improved on a weekly basis. In addition, the Mana.bio automation platform continuously leverages publicly available data with its unique software tools and so enriching the ever growing proprietary database that constantly improves its AI models' ability to design tissue-targeted LNPs [IMG: lipid nanoparticle formulations]
SUB-PAGE (https://mana.bio/team/) Team
Mana.bio is a seed stage biotech company leveraging data, machine learning and high throughput screening to design novel LNPs for targeted extrahepatic delivery of nucleic acid therapeutics and vaccines.Mana is founded and led by a team of repeat entrepreneurs and highly regarded experts in the field of drug delivery, machine learning and software development which are inspired by the potential of combining advanced technologies in biology and medicine. [H4] Founders [H2] Yogev Debbi Co-Founder & CEORepeat biotech entrepreneur, experienced in business leadership and applying software technologies in biology applications.Read More [H2] Roy Nevo Co-Founder & CTO Repeat biotech entrepreneur and a veteran software architect, skilled at leading rapidly developing innovative biotech products.Read More [H2] Prof. Avi Schroeder Scientific co-founderNanomedicine and drug delivery expert; Tenured Professor in the Chemical Engineering faculty at the Technion.Read More [H2] Dr. Kira Radinsky Scientific co-founderAI and data science expert pioneering predictive data mining and its applications in medicine.Read More [H4] Advisory Board [H2] Cory Sago, PhD Biomedical engineer and serial entrepreneur experienced in discovering lipid nanoparticles for targeted RNA delivery.Read More [H2] Peter Nell, PhD Experienced biopharma executive with over 20 years of experience advancing gene editing programs from R&D through commercialization.Read More [H2] Gaurav Sahay, PhD Expert in developing nanotechnology-based platforms for effective mRNA therapeutics, particularly for cystic fibrosis and retinal degeneration.Read More [H2] Barry Ticho, MD PhD Experienced drug developer and clinician leading multiple neurology and cardiology programs through clinical trials and commercializationRead More [H2] Prof. Eitan Kerem, MD Pediatric specialist and researcher who has made substantial contributions to improving cystic fibrosis patient care and advocacy.Read More [H2] Guy Van Meter Guy Van Meter is the CBO at Adimab, where he scaled the $5B+ antibody leader via 140+ major partnerships. He formerly led Pfizer’s RNA Business Development.Read More [H2] Prof. Jordan Green Prolific biomedical engineer, professor, and entrepreneur developing innovative genetic medicines and immunotherapies.Read More [H2] Lubo Nechev, PhD Renowned expert in RNAi therapeutics and lipid nanoparticle formulation with a proven track record in developing innovative solutions for gene delivery.Read More [H4] Investors [IMG: Nfx logo.png] [IMG: LionBird Logo.png] [IMG: a16z logo.png] [IMG: base4 logo small.png] [IMG: TRDF LOGO.JPG] [IMG: image.png] Using Mana’s proprietary platform we aim to create novel delivery solutions that will unlock the RNA and nucleic acid therapeutics potential, and treat genetic diseases across a wide range of unmet needs.
SUB-PAGE · THIN (https://mana.bio/fto/) LNP patents map | Mana.bio
[IMG: Mana bio FTO map v3.gif]
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 8 | 0 |
| /technology/ | 8 | 0 |
| /team/ | 10 | 0 |
| /fto/ | 8 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema
[
{
"@context": "https://schema.org/",
"@type": "LocalBusiness",
"name": "Mana.bio",
"url": "https://www.mana.bio",
"image": "https://static.wixstatic.com/media/e03eb4_366b084896d04ad3823cacfcd6b9dbbf~mv2.png",
"address": {
"@type": "PostalAddress",
"addressCountry": "IL",
"addressLocality": "Tel Aviv-Yafo"
}
},
{
"@context": "https://schema.org/",
"@type": "WebSite",
"name": "Mana.bio",
"url": "https://www.mana.bio"
}
]
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
Based on 784 businesses audited.
Mana.bio has 4.3 points more BS than the average for Medical Devices, Pharma & Biotech.
Medical Devices, Pharma & Biotech BS: Mana.bio (mana.bio)
Mana.bio presents as a credible, expert-led biotech venture that has unfortunately left its Wix-template ‘trust theatre’ (ghost reviews) active. While the underlying technical concepts are sound, the site currently functions more as an investor pitch deck than a scientific proof-of-concept. The distance between its ‘breakthrough’ claims and its lack of linked citations suggests a company in stealth-marketing mode rather than one ready for forensic scientific scrutiny.
Immediately remove the ‘review_count’ and ‘trust theatre’ flags from the Wix template, as generic reviews for a biotech firm are a massive BS signal. Replace the GIF on the FTO page with a searchable table of actual patent filing numbers or links to WIPO/USPTO records. Add sameAs properties to the schema for all named founders and advisors to link their academic and professional footprints. Transform the H2 paragraph on the Technology page into standard body text and use that space to link to a white paper or a technical poster that demonstrates the AI’s predictive accuracy.
The site strongly aligns with the Pharma & Biotech category, focusing specifically on lipid nanoparticle (LNP) delivery systems and gene therapy. The terminology used, such as ‘extrahepatic delivery’ and ‘nucleic acid therapeutics,’ is consistent with current industry-specific R&D trends.
“The score of 45 is primarily driven by the 'Trust and Proof' pillar (18/20) due to the presence of unverified reviews and a lack of external proof paths. The technical implementation errors (Authority Gaps) also contributed significantly. The score remains in the 'Moderate BS' range because the core technical language and named team members are highly specific to the industry, preventing a higher 'fluff' score.”
This training module utilizes a snapshot of public data from Mana.bio, captured on May 31, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to Mana.bio: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://mana.bio to view the most current version of its content and learn from the source what this company is about and what it offers.